CytomX Therapeutics, Inc.(CTMX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CytomX Therapeutics, Inc. (CTMX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTMX at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,927 of 2,962 stocks — the bottom half of the AI-ranked universe. CTMX scores in the top quartile across institutional flow (86.0). Areas of concern include revenue growth (0.3) and free cash flow (2.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CytomX Therapeutics, Inc. reports quarterly revenue of $1.4M, net income of $-20.7M, free cash flow of $-18.1M. Top institutional holders of CTMX by reported 13-F value include FMR, Kynam Capital Management, BlackRock, based on the most recent SEC filings. CTMX trades on the Nasdaq exchange and files with the SEC under CIK 1501989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CytomX Therapeutics, Inc. directly from SEC EDGAR.